ArticleBMC cancer2024
Development and validation of prediction models for papillary thyroid cancer structural recurrence using machine learning approaches.
Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Prediction models for postoperative recurrence in papillary thyroid carcinoma: a systematic review and critical appraisal.Frontiers in endocrinology · 2026Pooled it
- From Patient Selection to Surveillance: Artificial Intelligence Applications in Radioiodine Therapy - A Systematic Review.Nuclear medicine and molecular imaging · 2026Review
- Development and validation of a machine learning-based hierarchical classification model for predicting the early therapeutic response to initialAnnals of nuclear medicine · 2026Article
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer.Scientific reports · 2026Article
- Predicting Postoperative Survival in Patients With Malignant Biliary Obstruction Using an Interpretable Machine Learning Model: A Multicenter Study.Cancer medicine · 2026Article
- Nomogram for predicting papillary thyroid carcinoma risk combined with clinical, biochemical and ultrasonographic indicators.BMC cancer · 2026Article
- The Prediction of Pre-Eclampsia Using Low Fetal Fraction in a Machine Learning Model.Prenatal diagnosis · 2026Article
- Differentiated Thyroid Cancer Recurrence and Mortality Prognostic Factors: A Retrospective Cohort Study on 350 Adult Patients.Iranian journal of otorhinolaryngology · 2026Article
- CD31-associated vascular phenotyping using Doppler ultrasound and dual-energy CT for recurrence risk stratification in papillary thyroid cancer.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Explaining Risk Stratification in Differentiated Thyroid Cancer Using SHAP and Machine Learning Approaches.Biomedicines · 2025Article
- A novel hybrid deep learning and chaotic dynamics approach for thyroid cancer classification.Scientific reports · 2025Article
- Preoperative thyroglobulin antibody concentrations and prediction of papillary thyroid carcinoma recurrence.Endocrine · 2025Article
- Individualized survival prediction and risk stratification using machine learning for patients with malignant struma ovarii: a population-based study with external validation.Gland surgery · 2025Article
- Construction of a Multimodal Machine Learning Model for Papillary Thyroid Carcinoma Based on Pathomics and Ultrasound Radiomics Dataset.Data in brief · 2025Article
- Optimizing unsupervised feature engineering and classification pipelines for differentiated thyroid cancer recurrence prediction.BMC medical informatics and decision making · 2025Article
- Comparison of 46 Cytokines in Peripheral Blood Between Patients with Papillary Thyroid Cancer and Healthy Individuals with AI-Driven Analysis to Distinguish Between the Two Groups.Diagnostics (Basel, Switzerland) · 2025Article
- Development and validation of an interpretable machine learning model for predicting the risk of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study.BMC gastroenterology · 2025Article
- Development and validation of a gradient boosting machine-based model for predicting tumor-infiltrating lymphocyte proportions in breast cancer.American journal of translational research · 2025Article
- Machine learning and Shapley Additive exPlanations to predict metastasis of lymph nodes posterior to the recurrent laryngeal nerve in cN0 papillary thyroid carcinoma.Frontiers in oncology · 2025Article
- Quantitative analysis of studies that use artificial intelligence on thyroid cancer: a 20-year bibliometric analysis.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAlthough papillary thyroid cancer (PTC) patients are known to have an excellent prognosis, up to 30% of patients experience disease recurrence after initial treatment. Accurately predicting disease prognosis remains a challenge given that the predictive value of several predictors remains controversial. Thus, we investigated whether machine learning (ML) approaches based on comprehensive predictors can predict the risk of structural recurrence for PTC patients.
methodsA total of 2244 patients treated with thyroid surgery and radioiodine were included. Twenty-nine perioperative variables consisting of four dimensions (demographic characteristics and comorbidities, tumor-related variables, lymph node (LN)-related variables, and metabolic and inflammatory markers) were analyzed. We applied five ML algorithms-logistic regression (LR), support vector machine (SVM), extreme gradient boosting (XGBoost), random forest (RF), and neural network (NN)-to develop the models. The area under the receiver operating characteristic (AUC-ROC) curve, calibration curve, and variable importance were used to evaluate the models' performance.
resultsDuring a median follow-up of 45.5 months, 179 patients (8.0%) experienced structural recurrence. The non-stimulated thyroglobulin, LN dissection, number of LNs dissected, lymph node metastasis ratio, N stage, comorbidity of hypertension, comorbidity of diabetes, body mass index, and low-density lipoprotein were used to develop the models. All models showed a greater AUC (AUC = 0.738 to 0.767) than did the ATA risk stratification (AUC = 0.620, DeLong test: P < 0.01). The SVM, XGBoost, and RF model showed greater sensitivity (0.568, 0.595, 0.676), specificity (0.903, 0.857, 0.784), accuracy (0.875, 0.835, 0.775), positive predictive value (PPV) (0.344, 0.272, 0.219), negative predictive value (NPV) (0.959, 0.959, 0.964), and F1 score (0.429, 0.373, 0.331) than did the ATA risk stratification (sensitivity = 0.432, specificity = 0.770, accuracy = 0.742, PPV = 0.144, NPV = 0.938, F1 score = 0.216). The RF model had generally consistent calibration compared with the other models. The Tg and the LNR were the top 2 important variables in all the models, the N stage was the top 5 important variables in all the models.
conclusionsThe RF model achieved the expected prediction performance with generally good discrimination, calibration and interpretability in this study. This study sheds light on the potential of ML approaches for improving the accuracy of risk stratification for PTC patients.
trial registrationRetrospectively registered at www.chictr.org.cn (trial registration number: ChiCTR2300075574, date of registration: 2023-09-08).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.